{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:58:27Z","timestamp":1790402307427,"version":"4.1.0"},"reference-count":190,"publisher":"Bioscientifica","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ec.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Monoclonal antibodies blocking the programmed cell death-1 (PD-1) or its ligand (PD-L1) are a group of immune checkpoints inhibitors (ICIs) with proven antitumor efficacy. However, their use is complicated by immune-related adverse events (irAEs), including endocrine adverse events (eAEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>We review the incidence, time to onset and resolution rate of dysthyroidism induced by PD-1\/PD-L1 Ab, and the clinical, biological and radiological findings. We aim to discuss the potential mechanisms of PD-1\/PD-L1 Ab-induced dysthyroidism, and to propose a management algorithm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a literature search of available clinical trials regarding PD-1\/PD-L1 Ab in the PubMed database. We selected all English language clinical trials that included at least 100 patients. We also present selected case series or reports, retrospective studies and reviews related to this issue.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>In patients treated with PD-1 Ab, hypothyroidism occurred in 2\u201310.1% and hyperthyroidism occurred in 0.9\u20137.8%. When thyroiditis was reported separately, it occurred in 0.34\u20132.6%. Higher rates were reported when PD-1 Ab were associated with other ICI or chemotherapy. The median time to onset of hyperthyroidism and hypothyroidism after PD-1 Ab initiation was 23\u201345 days and 2\u20133.5 months, respectively. Regarding PD-L1 Ab, hypothyroidism occurred in 0\u201310% and hyperthyroidism in 0.5\u20132% of treated patients. The average time to onset of dysthyroidism after PD-L1 Ab was variable and ranged from 1 day after treatment initiation to 31 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Dysthyroidism occurs in up to 10% of patients treated with PD-1\/PD-L1 Ab. Hypothyroidism and reversible destructive thyroiditis are the most frequent endocrine adverse events (eAE) in PD-1\/PD-L1 treated patients. Immune and non-immune mechanisms are potentially involved, independently of the presence of thyroid antibodies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/ec-18-0079","type":"journal-article","created":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T06:50:09Z","timestamp":1525762209000},"page":"R196-R211","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":13,"title":["Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism"],"prefix":"10.1530","volume":"7","author":[{"given":"Jaafar","family":"Jaafar","sequence":"first","affiliation":[{"name":"1Division of Endocrinology and Diabetology, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Fernandez","sequence":"additional","affiliation":[{"name":"2Department of Oncology, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba","family":"Alwan","sequence":"additional","affiliation":[{"name":"1Division of Endocrinology and Diabetology, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Philippe","sequence":"additional","affiliation":[{"name":"1Division of Endocrinology and Diabetology, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"ref781","article-title":"MerckSharpDohmeCorp Prescribing Station Merck Co Inc available at https www merck com product usa pi circulars k keytruda keytruda pi pdf","author":"Keytruda","year":"2017","journal-title":"Information USA"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","article-title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial","volume":"17","year":"2016","journal-title":"Lancet Oncology"},{"key":"ref1211","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"ref1371","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","article-title":"PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma","volume":"374","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"ref1841","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1210\/jc.2014-4560","article-title":"Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies","volume":"100","year":"2015","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","article-title":"PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma","volume":"374","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"ref631","first-page":"232.e1","article-title":"A phase III study of durvalumab (MEDI4736) with or without tremelimumab for previously treated patients with advanced NSCLC: rationale and protocol design of the ARCTIC study","volume":"17","year":"2016","journal-title":"Clinical Lung Cancer"},{"key":"ref1931","article-title":"Toxicity management of immunotherapy for patients with metastatic melanoma","volume":"4","year":"2016","journal-title":"Annals of Translational Medicine"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","year":"2015","journal-title":"Lancet Oncology"},{"key":"ref1491","doi-asserted-by":"publisher","first-page":"01","DOI":"10.1016\/j.jtho.2016.09.009","article-title":"ORAL phase II trial of atezolizumab for patients with selected advanced updated efficacy and exploratory biomarker results topic medical oncology of https org","author":"NSCLC","journal-title":"Journal Thoracic Oncology"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","year":"2017","journal-title":"Lancet Oncology"},{"key":"ref961","article-title":"Toxicity management of immunotherapy for patients with metastatic melanoma","volume":"4","year":"2016","journal-title":"Annals of Translational Medicine"},{"key":"ref1571","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1470-2045(17)30240-1","article-title":"Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial","volume":"18","year":"2017","journal-title":"Lancet Oncology"},{"key":"ref561","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1634\/theoncologist.2017-0087","article-title":"FDA Approval Summary: atezolizumab for the treatment of patients with progressive advanced urothelial carcinoma after platinum-containing chemotherapy","volume":"22","year":"2017","journal-title":"Oncologist"},{"key":"ref1061","doi-asserted-by":"crossref","first-page":"246","DOI":"10.4143\/crt.2016.066","article-title":"Overexpression of PD-L1 and PD-L2 is associated with poor prognosis in patients with hepatocellular carcinoma","volume":"49","year":"2017","journal-title":"Cancer Research and Treatment"},{"key":"ref1801","doi-asserted-by":"crossref","first-page":"896","DOI":"10.2967\/jnumed.106.039024","article-title":"Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland","volume":"48","year":"2007","journal-title":"Journal of Nuclear Medicine"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","year":"2016","journal-title":"Lancet Oncology"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2016.4059","article-title":"Association of pembrolizumab with tumor response and survival among patients with advanced melanoma","volume":"315","year":"2016","journal-title":"JAMA"},{"key":"ref1351","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","year":"2016","journal-title":"Lancet Oncology"},{"key":"ref1701","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1210\/jc.2017-00448","article-title":"Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms","volume":"102","year":"2017","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/107327481402100308","article-title":"PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy","volume":"21","year":"2014","journal-title":"Cancer Control"},{"key":"ref1261","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1470-2045(17)30240-1","article-title":"Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial","volume":"18","year":"2017","journal-title":"Lancet Oncology"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"S304","DOI":"10.1016\/j.jtho.2016.09.090","article-title":"PS01.55: IMpower010: phase III study of atezolizumab vs BSC after adjuvant chemotherapy in patients with completely resected NSCLC: topic: medical oncology","volume":"11","year":"2016","journal-title":"Journal of Thoracic Oncology"},{"key":"ref521","doi-asserted-by":"publisher","first-page":"01","DOI":"10.1016\/j.jtho.2016.09.009","article-title":"ORAL phase II trial of atezolizumab for patients with selected advanced updated efficacy and exploratory biomarker results topic medical oncology of https org","author":"NSCLC","journal-title":"Journal Thoracic Oncology"},{"key":"ref1101","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","year":"2002","journal-title":"Nature Medicine"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"246","DOI":"10.4143\/crt.2016.066","article-title":"Overexpression of PD-L1 and PD-L2 is associated with poor prognosis in patients with hepatocellular carcinoma","volume":"49","year":"2017","journal-title":"Cancer Research and Treatment"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"ref1781","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American Thyroid Association Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","year":"2016","journal-title":"Thyroid"},{"key":"ref751","first-page":"575","article-title":"Nivolumab-induced thyroid dysfunction","volume":"46","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"ref1721","first-page":"575","article-title":"Nivolumab-induced thyroid dysfunction","volume":"46","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"ref1731","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1089\/thy.2016.0562","article-title":"Clinical features of nivolumab-induced thyroiditis: a case series study","volume":"27","year":"2017","journal-title":"Thyroid"},{"key":"ref1541","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.1158\/1078-0432.CCR-17-0540","article-title":"U.S. Food and Drug Administration Approval Summary: atezolizumab for metastatic non-small cell lung cancer","volume":"23","year":"2017","journal-title":"Clinical Cancer Research"},{"key":"ref1131","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(16)30496-X","article-title":"Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1\/2 trial","volume":"17","year":"2016","journal-title":"Lancet Oncology"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/jco.2013.31.15_suppl.3000","article-title":"A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors","volume":"31","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/intimm\/dxq049","article-title":"PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1","volume":"22","year":"2010","journal-title":"International Immunology"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","article-title":"Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial","volume":"17","year":"2016","journal-title":"Lancet Oncology"},{"key":"ref811","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American Thyroid Association Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","year":"2016","journal-title":"Thyroid"},{"key":"ref1601","first-page":"232.e1","article-title":"A phase III study of durvalumab (MEDI4736) with or without tremelimumab for previously treated patients with advanced NSCLC: rationale and protocol design of the ARCTIC study","volume":"17","year":"2016","journal-title":"Clinical Lung Cancer"},{"key":"ref1871","doi-asserted-by":"crossref","first-page":"950","DOI":"10.4049\/jimmunol.1401686","article-title":"Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo","volume":"194","year":"2015","journal-title":"Journal of Immunology"},{"key":"ref791","article-title":"Prescribing New York available at https packageinserts bms com pi pi opdivo pdf","author":"Bristol","year":"2018","journal-title":"Information USA"},{"key":"ref1021","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1002\/eji.200324228","article-title":"Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses","volume":"33","year":"2003","journal-title":"European Journal of Immunology"},{"key":"ref1921","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/jco.2011.29.15_suppl.2505","article-title":"Evaluation of serum IL-17 levels during ipilimumab therapy: correlation with colitis","volume":"29","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"ref1011","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","year":"2000","journal-title":"Journal of Experimental Medicine"},{"key":"ref1111","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/107327481402100308","article-title":"PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy","volume":"21","year":"2014","journal-title":"Cancer Control"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"ref1881","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1172\/JCI96798","article-title":"Early B cell changes predict autoimmunity following combination immune checkpoint blockade","volume":"128","year":"2018","journal-title":"Journal of Clinical Investigation"},{"key":"ref1811","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/MNM.0b013e328013eaf7","article-title":"The significance of FDG uptake in bilateral thyroid glands","volume":"28","year":"2007","journal-title":"Nuclear Medicine Communications"},{"key":"ref71","first-page":"656340","article-title":"Programmed death ligand 2 in cancer-induced immune suppression","volume":"2012","year":"2012","journal-title":"Clinical and Developmental Immunology"},{"key":"ref1191","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial","volume":"17","year":"2016","journal-title":"Lancet Oncology"},{"key":"ref1911","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"ref1121","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","year":"2017","journal-title":"Lancet Oncology"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","year":"1992","journal-title":"EMBO Journal"},{"key":"ref971","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","year":"1992","journal-title":"EMBO Journal"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"ref1511","doi-asserted-by":"publisher","first-page":"01","DOI":"10.1016\/j.jtho.2016.09.092","article-title":"ChavezASandlerAGiacconneG a phase III study of atezolizumab with carboplatin and etoposide in patients with extensive - stage topic medical oncology of https org","author":"IMpower","journal-title":"PS Journal Thoracic Oncology"},{"key":"ref1461","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","year":"2016","journal-title":"Lancet"},{"key":"ref1771","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0140-6736(16)00278-6","article-title":"Hyperthyroidism","volume":"388","year":"2016","journal-title":"Lancet"},{"key":"ref861","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1055\/s-0042-119528","article-title":"Hypothyroidism in cancer patients on immune checkpoint inhibitors with anti-PD1 agents: insights on underlying mechanisms","volume":"125","year":"2017","journal-title":"Experimental and Clinical Endocrinology and Diabetes"},{"key":"ref1521","doi-asserted-by":"crossref","first-page":"S304","DOI":"10.1016\/j.jtho.2016.09.090","article-title":"PS01.55: IMpower010: phase III study of atezolizumab vs BSC after adjuvant chemotherapy in patients with completely resected NSCLC: topic: medical oncology","volume":"11","year":"2016","journal-title":"Journal of Thoracic Oncology"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1200\/JCO.2015.63.7421","article-title":"Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study","volume":"34","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"ref1041","first-page":"656340","article-title":"Programmed death ligand 2 in cancer-induced immune suppression","volume":"2012","year":"2012","journal-title":"Clinical and Developmental Immunology"},{"key":"ref1251","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","year":"2015","journal-title":"Lancet Oncology"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","article-title":"Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors","volume":"21","year":"2015","journal-title":"Clinical Cancer Research"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","article-title":"Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes","volume":"8","year":"1996","journal-title":"International Immunology"},{"key":"ref871","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1210\/jc.2014-4560","article-title":"Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies","volume":"100","year":"2015","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","article-title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study","volume":"18","year":"2017","journal-title":"Lancet Oncology"},{"key":"ref1671","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","year":"2014","journal-title":"Nature"},{"key":"ref1401","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(17)30007-4","article-title":"Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study","volume":"18","year":"2017","journal-title":"Lancet Oncology"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial","volume":"17","year":"2016","journal-title":"Lancet Oncology"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"e172411","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1\/2 open-label study","volume":"3","year":"2017","journal-title":"JAMA Oncology"},{"key":"ref731","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1210\/jc.2017-00448","article-title":"Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms","volume":"102","year":"2017","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref1891","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nm.4321","article-title":"Is autoimmunity the Achilles\u2019 heel of cancer immunotherapy?","volume":"23","year":"2017","journal-title":"Nature Medicine"},{"key":"ref921","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nm.4321","article-title":"Is autoimmunity the Achilles\u2019 heel of cancer immunotherapy?","volume":"23","year":"2017","journal-title":"Nature Medicine"},{"key":"ref1561","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","article-title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial","volume":"17","year":"2016","journal-title":"Lancet Oncology"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","year":"2017","journal-title":"Lancet"},{"key":"ref711","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","article-title":"Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer","volume":"34","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"ref741","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1210\/jc.2016-2300","article-title":"Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab","volume":"101","year":"2016","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref771","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40425-017-0213-x","article-title":"Nivolumab induced myxedema crisis","volume":"5","year":"2017","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"ref1171","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1200\/JCO.2016.66.9929","article-title":"Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer","volume":"34","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"ref1321","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/annonc\/mdx008","article-title":"Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial","volume":"28","year":"2017","journal-title":"Annals of Oncology"},{"key":"ref1761","article-title":"Prescribing New York available at https packageinserts bms com pi pi opdivo pdf","author":"Bristol","year":"2018","journal-title":"Information USA"},{"key":"ref761","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1089\/thy.2016.0562","article-title":"Clinical features of nivolumab-induced thyroiditis: a case series study","volume":"27","year":"2017","journal-title":"Thyroid"},{"key":"ref911","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1172\/JCI96798","article-title":"Early B cell changes predict autoimmunity following combination immune checkpoint blockade","volume":"128","year":"2018","journal-title":"Journal of Clinical Investigation"},{"key":"ref691","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"ref991","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/intimm\/10.10.1563","article-title":"Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses","volume":"10","year":"1998","journal-title":"International Immunology"},{"key":"ref951","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/jco.2011.29.15_suppl.2505","article-title":"Evaluation of serum IL-17 levels during ipilimumab therapy: correlation with colitis","volume":"29","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"ref1431","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1200\/JCO.2015.63.7421","article-title":"Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study","volume":"34","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"ref671","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"ref1141","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","article-title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study","volume":"18","year":"2017","journal-title":"Lancet Oncology"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.2147\/OTT.S134589","article-title":"Overexpression of PD-L2 is associated with shorter relapse-free survival in patients with malignant salivary gland tumors","volume":"10","year":"2017","journal-title":"OncoTargets and Therapy"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1200\/JCO.2016.66.9861","article-title":"Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer","volume":"34","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","year":"2017","journal-title":"Lancet"},{"key":"ref1821","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","year":"2017","journal-title":"Annals of Oncology"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1470-2045(15)00544-6","article-title":"Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study","volume":"17","year":"2016","journal-title":"Lancet Oncology"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(16)30496-X","article-title":"Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1\/2 trial","volume":"17","year":"2016","journal-title":"Lancet Oncology"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1200\/JCO.2016.66.9929","article-title":"Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer","volume":"34","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"ref1751","article-title":"MerckSharpDohmeCorp Prescribing Station Merck Co Inc available at https www merck com product usa pi circulars k keytruda keytruda pi pdf","author":"Keytruda","year":"2017","journal-title":"Information USA"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","year":"2002","journal-title":"PNAS"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1200\/JCO.2016.71.9476","article-title":"Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH)","volume":"35","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"ref891","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1172\/JCI99036","article-title":"B cells as biomarkers: predicting immune checkpoint therapy adverse events","volume":"128","year":"2018","journal-title":"Journal of Clinical Investigation"},{"key":"ref941","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"ref1581","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1470-2045(15)00544-6","article-title":"Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study","volume":"17","year":"2016","journal-title":"Lancet Oncology"},{"key":"ref981","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","article-title":"Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes","volume":"8","year":"1996","journal-title":"International Immunology"},{"key":"ref851","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","year":"2017","journal-title":"Annals of Oncology"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"ref681","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"ref661","first-page":"1035","article-title":"Predictive factors of nivolumab-induced hypothyroidism in patients with non-small cell lung cancer","volume":"31","year":"2017","journal-title":"In Vivo"},{"key":"ref841","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/MNM.0b013e328013eaf7","article-title":"The significance of FDG uptake in bilateral thyroid glands","volume":"28","year":"2007","journal-title":"Nuclear Medicine Communications"},{"key":"ref901","doi-asserted-by":"crossref","first-page":"950","DOI":"10.4049\/jimmunol.1401686","article-title":"Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo","volume":"194","year":"2015","journal-title":"Journal of Immunology"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","year":"2000","journal-title":"Journal of Experimental Medicine"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial","volume":"17","year":"2016","journal-title":"Lancet Oncology"},{"key":"ref701","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","year":"2014","journal-title":"Nature"},{"key":"ref1031","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","year":"2001","journal-title":"Nature Immunology"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1002\/eji.200324228","article-title":"Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses","volume":"33","year":"2003","journal-title":"European Journal of Immunology"},{"key":"ref1341","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"ref541","doi-asserted-by":"publisher","first-page":"01","DOI":"10.1016\/j.jtho.2016.09.092","article-title":"ChavezASandlerAGiacconneG a phase III study of atezolizumab with carboplatin and etoposide in patients with extensive - stage topic medical oncology of https org","author":"IMpower","journal-title":"PS Journal Thoracic Oncology"},{"key":"ref1531","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1634\/theoncologist.2017-0087","article-title":"FDA Approval Summary: atezolizumab for the treatment of patients with progressive advanced urothelial carcinoma after platinum-containing chemotherapy","volume":"22","year":"2017","journal-title":"Oncologist"},{"key":"ref801","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0140-6736(16)00278-6","article-title":"Hyperthyroidism","volume":"388","year":"2016","journal-title":"Lancet"},{"key":"ref1181","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1200\/JCO.2016.66.9861","article-title":"Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer","volume":"34","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"ref1471","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","year":"2017","journal-title":"Lancet"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.1158\/1078-0432.CCR-17-0540","article-title":"U.S. Food and Drug Administration Approval Summary: atezolizumab for metastatic non-small cell lung cancer","volume":"23","year":"2017","journal-title":"Clinical Cancer Research"},{"key":"ref1631","first-page":"1035","article-title":"Predictive factors of nivolumab-induced hypothyroidism in patients with non-small cell lung cancer","volume":"31","year":"2017","journal-title":"In Vivo"},{"key":"ref1851","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1158\/2326-6066.CIR-17-0208","article-title":"Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy","volume":"5","year":"2017","journal-title":"Cancer Immunology Research"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","year":"2016","journal-title":"Lancet"},{"key":"ref1381","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","article-title":"Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial","volume":"17","year":"2016","journal-title":"Lancet Oncology"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","year":"2016","journal-title":"Lancet"},{"key":"ref1331","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"ref1421","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/jco.2013.31.15_suppl.3000","article-title":"A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors","volume":"31","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"ref1901","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1002\/cncr.30444","article-title":"Immune and molecular correlates in melanoma treated with immune checkpoint blockade","volume":"123","year":"2017","journal-title":"Cancer"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(16)30126-7","article-title":"Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial","volume":"17","year":"2016","journal-title":"Lancet Oncology"},{"key":"ref931","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1002\/cncr.30444","article-title":"Immune and molecular correlates in melanoma treated with immune checkpoint blockade","volume":"123","year":"2017","journal-title":"Cancer"},{"key":"ref1241","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","year":"2015","journal-title":"Lancet Oncology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/intimm\/10.10.1563","article-title":"Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses","volume":"10","year":"1998","journal-title":"International Immunology"},{"key":"ref1361","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial","volume":"17","year":"2016","journal-title":"Lancet Oncology"},{"key":"ref1661","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","year":"2001","journal-title":"Nature Immunology"},{"key":"ref1641","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"ref1741","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40425-017-0213-x","article-title":"Nivolumab induced myxedema crisis","volume":"5","year":"2017","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"ref1221","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"ref1451","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","year":"2016","journal-title":"Lancet"},{"key":"ref1081","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","year":"2002","journal-title":"PNAS"},{"key":"ref1831","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1055\/s-0042-119528","article-title":"Hypothyroidism in cancer patients on immune checkpoint inhibitors with anti-PD1 agents: insights on underlying mechanisms","volume":"125","year":"2017","journal-title":"Experimental and Clinical Endocrinology and Diabetes"},{"key":"ref1161","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","year":"2016","journal-title":"Lancet Oncology"},{"key":"ref1861","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1172\/JCI99036","article-title":"B cells as biomarkers: predicting immune checkpoint therapy adverse events","volume":"128","year":"2018","journal-title":"Journal of Clinical Investigation"},{"key":"ref1611","doi-asserted-by":"crossref","first-page":"e172411","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1\/2 open-label study","volume":"3","year":"2017","journal-title":"JAMA Oncology"},{"key":"ref1791","doi-asserted-by":"crossref","first-page":"988","DOI":"10.4158\/EP12280.GL","article-title":"Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association","volume":"18","year":"2012","journal-title":"Endocrine Practice"},{"key":"ref1091","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"ref1711","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1210\/jc.2016-2300","article-title":"Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab","volume":"101","year":"2016","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"ref881","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1158\/2326-6066.CIR-17-0208","article-title":"Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy","volume":"5","year":"2017","journal-title":"Cancer Immunology Research"},{"key":"ref831","doi-asserted-by":"crossref","first-page":"896","DOI":"10.2967\/jnumed.106.039024","article-title":"Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland","volume":"48","year":"2007","journal-title":"Journal of Nuclear Medicine"},{"key":"ref721","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","article-title":"Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management","volume":"58","year":"2017","journal-title":"Cancer Treatment Reviews"},{"key":"ref1551","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1158\/2326-6066.CIR-15-0059","article-title":"Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells","volume":"3","year":"2015","journal-title":"Cancer Immunology Research"},{"key":"ref1441","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","year":"2014","journal-title":"Nature"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"ref1281","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00280-016-3237-x","article-title":"Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)","volume":"79","year":"2017","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"ref1411","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(17)30007-4","article-title":"Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study","volume":"18","year":"2017","journal-title":"Lancet Oncology"},{"key":"ref1651","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"ref1691","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","article-title":"Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management","volume":"58","year":"2017","journal-title":"Cancer Treatment Reviews"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","year":"2015","journal-title":"Lancet Oncology"},{"key":"ref1071","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.2147\/OTT.S134589","article-title":"Overexpression of PD-L2 is associated with shorter relapse-free survival in patients with malignant salivary gland tumors","volume":"10","year":"2017","journal-title":"OncoTargets and Therapy"},{"key":"ref1231","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","year":"2002","journal-title":"Nature Medicine"},{"key":"ref581","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1158\/2326-6066.CIR-15-0059","article-title":"Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells","volume":"3","year":"2015","journal-title":"Cancer Immunology Research"},{"key":"ref1391","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"ref821","doi-asserted-by":"crossref","first-page":"988","DOI":"10.4158\/EP12280.GL","article-title":"Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association","volume":"18","year":"2012","journal-title":"Endocrine Practice"},{"key":"ref1001","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","year":"1999","journal-title":"Immunity"},{"key":"ref1051","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/intimm\/dxq049","article-title":"PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1","volume":"22","year":"2010","journal-title":"International Immunology"},{"key":"ref1301","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","year":"2014","journal-title":"Lancet"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/annonc\/mdx008","article-title":"Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial","volume":"28","year":"2017","journal-title":"Annals of Oncology"},{"key":"ref1291","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"ref1311","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2016.4059","article-title":"Association of pembrolizumab with tumor response and survival among patients with advanced melanoma","volume":"315","year":"2016","journal-title":"JAMA"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","year":"2016","journal-title":"Lancet Oncology"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","year":"2014","journal-title":"Nature"},{"key":"ref1201","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(16)30126-7","article-title":"Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial","volume":"17","year":"2016","journal-title":"Lancet Oncology"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","year":"1999","journal-title":"Immunity"},{"key":"ref1681","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","article-title":"Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer","volume":"34","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"ref1501","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","year":"2017","journal-title":"Lancet"},{"key":"ref1151","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"ref1271","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","article-title":"Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors","volume":"21","year":"2015","journal-title":"Clinical Cancer Research"},{"key":"ref1481","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1200\/JCO.2016.71.9476","article-title":"Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH)","volume":"35","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00280-016-3237-x","article-title":"Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)","volume":"79","year":"2017","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","year":"2014","journal-title":"Lancet"}],"container-title":["Endocrine Connections"],"original-title":[],"link":[{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/7\/5\/EC-18-0079.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/7\/5\/EC-18-0079.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:42:49Z","timestamp":1784554969000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/ec\/article\/7\/5\/R196-R211\/309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":190,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.1530\/ec-18-0079","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5]]}}}